Importance Approximately 43 720 new cases of thyroid carcinoma are expected to be
diagnosed in 2023 in the US. Five-year relative survival is approximately 98.5%. This review …

The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

Background: The aim of this study was to describe the oncologic outcomes of patients with
BRAFV600E-mutated anaplastic thyroid cancer (ATC) who had neoadjuvant BRAF-directed …

Anaplastic thyroid cancer (ATC) is an infrequent thyroid tumor that usually occurs in elderly
patients. There is often a history of previous differentiated thyroid cancer suggesting a …

Tumours can arise from thyroid follicular cells if they acquire driver mutations that
constitutively activate the MAPK signalling pathway. In addition, a limited set of additional …

Background: The dabrafenib plus trametinib combination (DT) has revolutionized the
treatment of BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC). However …

Differentiated thyroid cancers (DTCs) are primarily initiated by mutations that activate the
MAPK signaling cascade, typically at BRAF or RAS oncoproteins. DTCs can evolve to more …

Background: Anaplastic thyroid cancer (ATC) is uniformly lethal. BRAFV600E mutation is
present in 45% of patients with ATC. Targeted therapy with combined BRAF and MEK …

Purpose: RAS mutations occur across the spectrum of thyroid neoplasms, and more tools
are needed for better prognostication. The objective of this study was to evaluate how …

Objectives Anaplastic thyroid carcinoma (ATC) has a poor survival. The combination of
Dabrafenib plus Trametinib (DT) had a significant impact in survival of BRAF p. V600E …